Development and validation of a high‐performance liquid chromatography–tandem mass spectrometric method for simultaneous determination of bupropion, quetiapine and escitalopram in human plasma. (29th September 2014)

• Record Type: Journal Article
• Authors: Park, Semin; Park, Chul‐Soo; Lee, Sung Joong; Cha, Boseok; Cho, Young Ah; Song, Yi; Yu, Eun Ae; Kim, Gon‐Sup; Jin, Jong Sung; Abd El‐Aty, A. M.; El‐Banna, H. A.; Hacımüftüoğlu, Ahmet; Shim, Jae‐Han; Shin, Sung Chul
• Is Part Of: Biomedical chromatography. Volume 29:Number 4(2015:Apr.)
• Page Start: 612
• Page End: 618
• Publication Date: 2014-09-29
• Subjects: major depressive disorder -- bupropion -- quetiapine -- escitalopram -- LC/MS/MS; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.3322
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: In the present study, an effective high performance liquid chromatography–tandem mass spectrometric (HPLC/MS/MS) method was developed and validated to simultaneously determine bupropion (BUP), quetiapine (QUE) and escitalopram (ESC) in human plasma using carbidopa as the internal standard. Chromatographic separation was achieved on a Waters Sun Fire C18 column using reversed‐phase chromatography. The MS/MS experiment was performed in positive ion multiple reaction monitoring mode to produce product ions of m/z 240.3 → 184.2 for BUP, 384.2 → 253.1 for QUE, 325.3 → 109.3 for ESC and 227.2 → 181.2 for the internal standard. The method showed good linearity ( R 2 ≥ 0.997), precision (relative standard deviation ≤7.5%), satisfactory intra‐ and interday accuracy (88.4–113.0%) and acceptable extraction recovery (87.2–115.0%), matrix effect (84.5.5−108.7%) and stability (92.3−103.5%). The method was successfully applied to determine the concentrations of BUP, QUE and ESC in human plasma samples. Copyright © 2014 John Wiley & Sons, Ltd.